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Reactive oxygen species (ROS) are important pathophysiological molecules involved in
vital cellular processes. They are extremely harmful at high concentrations because they
promote the generation of radicals and the oxidation of lipids, proteins, and nucleic
acids, which can result in apoptosis. An imbalance of ROS and a disturbance of
redox homeostasis are now recognized as a hallmark of complex diseases. Considering
that ROS levels are significantly increased in cancer cells due to mitochondrial
dysfunction, ROS metabolism has been targeted for the development of efficient
treatment strategies, and antioxidants are used as potential chemotherapeutic drugs.
However, initial ROS-focused clinical trials in which antioxidants were supplemented to
patients provided inconsistent results, i.e., improved treatment or increased malignancy.
These different outcomes may result from the highly heterogeneous redox responses of
tumors in different patients. Hence, population-based treatment strategies are unsuitable
and patient-tailored therapeutic approaches are required for the effective treatment
of patients. Moreover, due to the crosstalk between ROS, reducing equivalents [e.g.,
NAD(P)H] and central metabolism, which is heterogeneous in cancer, finding the best
therapeutic target requires the consideration of system-wide approaches that are
capable of capturing the complex alterations observed in all of the associated pathways.
Systems biology and engineering approaches may be employed to overcome these
challenges, together with tools developed in personalized medicine. However, ROS- and
redox-based therapies have yet to be addressed by these methodologies in the context
of disease treatment. Here, we review the role of ROS and their coupled redox partners in
tumorigenesis. Specifically, we highlight some of the challenges in understanding the role
of hydrogen peroxide (H2O2), one of the most important ROS in pathophysiology in the
progression of cancer. We also discuss its interplay with antioxidant defenses, such as
the coupled peroxiredoxin/thioredoxin and glutathione/glutathione peroxidase systems,
and its reducing equivalent metabolism. Finally, we highlight the need for system-level and
patient-tailored approaches to clarify the roles of these systems and identify therapeutic
targets through the use of the tools developed in personalized medicine.
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INTRODUCTION
Redoxmetabolism is closely intertwinedwith cell physiology, and
reactive oxygen species (ROS) are central players in health and
disease. For instance, these oxygen-derived species are involved
in cancer (Reuter et al., 2010), neurodegenerative diseases
(Sultana et al., 2006), aging (Höhn et al., 2013), and diabetes
(Evans et al., 2002). They are produced intracellularly by several
processes and dedicated enzymes, such as NADPH oxidases
(Nauseef, 2008) and in multiple cellular compartments (Messner
and Imlay, 2002; Chen et al., 2008; Murphy, 2009; Brown and
Borutaite, 2012). Due to their high membrane permeability
(Chance et al., 1979), extracellularly produced ROS (Hampton
et al., 1998; Babior et al., 2002) may quickly enter cells, or they
may diffuse across compartments (Bienert et al., 2007; Marchissio
et al., 2012). In many diseases, imbalances in ROS metabolism
lead to oxidative stress. As result, cells face toxic outcomes of
protein, lipid, and nucleic acid oxidation (Garrison, 1987; Cooke
et al., 2003; Smith and Murphy, 2008; Figure 1A). For instance,
DNA oxidation by ROS promotes mutagenesis, cancer initiation,
and progression (Shibutani et al., 1991; Cooke et al., 2003;
Sabharwal and Schumacker, 2014), and at high concentrations,
ROS may cause cell apoptosis (Gao et al., 2013).
In turn, low ROS concentrations have important physiological
roles (D’Autréaux and Toledano, 2007). They regulate cell-cycle
progression (Havens et al., 2006), proliferation (Choe et al., 2012),
growth (Arnold et al., 2001), and important signaling processes
(Finkel, 2011; Rigoulet et al., 2011). For instance, hydrogen
peroxide (H2O2) regulates the activity of kinases (Gotoh and
Cooper, 1998; Paulsen et al., 2012), which control proliferation,
differentiation, and apoptosis. NFE2L2 (also known as NRF2)
responds to oxidative stress and regulates GSH biosynthesis
and reduction, the expression of several proteins involved
in antioxidant defense (glutathione peroxidases, transferases,
peroxiredoxins, thioredoxins, and thioredoxin reductases), and
NADPH production (Gorrini et al., 2013). Many of these redox-
regulated processes are not directly controlled by ROS but
rather by their redox partners. For instance, redox signaling
transduction is often mediated by peroxiredoxins, thioredoxins,
and other thiol-reacting proteins (Saitoh et al., 1998; Giannoni
et al., 2005; Morinaka et al., 2011). These proteins ensure
the high specificity required for efficient signaling transduction
(Nagy and Winterbourn, 2010; Winterbourn, 2013; Marinho
et al., 2014; Netto and Antunes, 2016). Together with other
cellular antioxidants, such as catalases and dismutases, these
redox systems prevent toxic ROS accumulation while permitting
special-temporal selectivity and the maintenance of important
redox signaling functions.
In cancer, mitochondrial dysfunction and metabolic changes
promote constant oxidative stress (Szatrowski and Nathan, 1991;
Hileman et al., 2004); however, this does not result in apoptosis.
Cancer cells promote the expression of antioxidant defenses or
reducing equivalents that enable their activity (Janssen et al.,
1999; Miranda et al., 2000; Hileman et al., 2004), thus avoiding
ROS-induced apoptosis and enabling proliferation, despite high
mutagenesis (Toyokuni et al., 1995; Kondo et al., 1999) and
metastasis (Ishikawa et al., 2008; Figure 1B). ROS closely interact
with iron (Galaris et al., 2008) and central (Robbins et al., 2012;
Hart et al., 2015; Miar et al., 2015) metabolism, and they are
controlled by several transcription factors and tumor suppressors
(Gao et al., 2007; Frohlich et al., 2008; Gupta et al., 2012;
Gorrini et al., 2013; Hornsveld and Dansen, 2016). Additionally,
antioxidant enzymes may display high or low expression in
cancer cells (Ray et al., 2000; Oltra et al., 2001; Skrzydlewska et al.,
2005; Glorieux et al., 2015), suppress tumorigenesis or promote
metastasization (Zhao et al., 2001; Liu et al., 2012; Robbins et al.,
2012; Miar et al., 2015), and display synergistic responses (Harris
et al., 2015). As result, systematic approaches may capture these
complex responses and provide insights into the mechanisms
underlying the diverse phenotypic responses in cancer.
Systems biology presents promising approaches for capturing
and studying complex cellular responses (Mardinoglu et al.,
2013b; Ghaffari et al., 2015b). The application of such frameworks
to clinical challenges is referred to as systems or network
medicine (Mardinoglu and Nielsen, 2012, 2016). The complexity
of biological pathways in cells and tissues may be captured
through reconstruction of biological networks, including
genome-scale metabolic models (GEMs), transcriptional
regulatory networks, protein–protein interaction networks,
and signaling networks, in an integrated approach that aims to
understand entire cell processes at the systems level (Mardinoglu
and Nielsen, 2015; Zhang et al., 2016). These networks may also
be integrated with each other for a holistic understanding of the
relationships between cellular networks, function, and disease
(Bjornson et al., 2016; Lee et al., 2016; Mardinoglu and Uhlén,
2016). Generation of omics data for major human tissues enabled
the generation of comprehensive biological networks (Kampf
et al., 2014a; Lindskog et al., 2015; Uhlén et al., 2015, 2016; Thul
et al., 2017), which have been successfully employed in revealing
the underlying mechanisms involved in the occurrence of
obesity (Mardinoglu et al., 2013a, 2014b, 2015a), type 2 diabetes
(Väremo et al., 2015), non-alcoholic fatty liver disease (Kampf
et al., 2014b; Mardinoglu et al., 2014a, in press; Hyötyläinen
et al., 2016), and cancer (Agren et al., 2012, 2014; Weinstein
et al., 2013; Zack et al., 2013; Leiserson et al., 2014; Yizhak et al.,
2014b; Aran et al., 2015; Bjornson et al., 2015; Peng et al., 2015;
Elsemman et al., 2016). Personalized models have also been
used in the identification of potential therapeutic targets and
biomarkers (Faratian et al., 2009; Agren et al., 2014; Bjornson
et al., 2015; Mardinoglu et al., 2017; Nielsen, 2017). To date, small
scale redox networks have also been analyzed (Zhang et al., 2010;
Zhou et al., 2011; Zhan et al., 2012). However, despite extensive
evidence highlighting the importance of ROS, antioxidants
and other redox players in cancer, systems approaches have
yet to systematically examine the role of redox metabolism
in this disease and uncover potential personalized treatment
strategies.
Here, we highlight some recent findings about important
biological processes that are crucial in tumorigenesis: ROS,
their redox partners, and reducing equivalents. We start
by overviewing some of the main biochemical properties
of ROS and their effectors. We then discuss the role of
antioxidants and their reactions in tumorigenesis, focusing
on thiols and reducing equivalents due to their importance
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FIGURE 1 | Imbalances in ROS and redox cycles lead to contrasting outcomes in normal and cancer cells. (A) ROS are intracellularly produced by NADPH oxidases
and dual oxidases (NOX/DUOX) through mitochondrial oxidative phosphorylation and in peroxisomes. Their interconversion (orange circle) occurs through enzyme
catalyzed and non-catalyzed reactions. For instance, metal-catalyzed Fenton reactions produce HO• from O•−2 and H2O2. Under low ROS levels, these oxidants
control important signaling reactions, activating transcription factors, regulating pathways and controlling cell growth and differentiation. Under high ROS levels,
oxidation of lipids, nucleic acids, and proteins is toxic and may disturb pathways and lead to cell death. (B) Normal and cancer cells present important differences in
their responses to oxidative stress. Under normal conditions, ROS production is low and antioxidant defenses are sufficient to prevent toxic damage. Under oxidative
stress, the promoted production of ROS overcomes the cell’s capacity for detoxification and results in increased toxic damage and pathway disruption, which may
lead to mitochondrial dysfunction, mutagenesis and ultimately apoptosis. In turn, cancer cells are under constant oxidative stress, which through upregulation of
antioxidant defenses, prevents apoptosis while maintaining ROS toxicity. Arrows indicate fluxes, increasing from dashed to continuous, in red. O•−2 , superoxide;
H2O2, hydrogen peroxide; HO
•, hydroxyl radical; SOD, superoxide dismutase.
in ROS and redox homeostasis. Finally, given the high
heterogeneity of redox responses and the intricate crosstalk
between redox and central metabolism, we highlight how
system-level and patient-tailored approaches may help to
identify potential cancer targets and provide mechanistic
insights into redox cancer responses. These discussions do not
aim to be exhaustive descriptions of all biological processes
and regulators of redox homeostasis, and the interested
reader may find excellent reviews on these topics elsewhere
(e.g., Gao et al., 2007; Frohlich et al., 2008; Gupta et al., 2012;
Gorrini et al., 2013; Hornsveld and Dansen, 2016).
BIOCHEMISTRY OF ROS AND REDOX
SYSTEMS
Molecular oxygen freely diffuses across cell membranes and
promotes the formation of intracellular ROS through electron
abstraction. ROS may be classified as radicals and non-radicals.
Radicals have unpaired electrons and include superoxide (O•−2 )
and the hydroxyl (HO•) radicals. Non-radical ROS do not have
unpaired electrons, and they include H2O2. Here, we focus on
these three ROS due to their patho-physiological importance.
ROS metabolism yields many other less reactive, abundant,
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or stable ROS and is highly intertwined with other important
reactive species (such as Reactive Nitrogen Species, Weidinger
and Kozlov, 2015).
ROS are formed in several intracellular compartments. Most
notably, they are produced in peroxisomes through fatty acid
oxidation (Fransen et al., 2012), inmitochondria during oxidative
phosphorylation and in the cellular and intracellular membranes
by NADPH oxidases (EC 1.6.3.1; Nauseef, 2008; Kowaltowski
et al., 2009; Murphy, 2009; Brown and Borutaite, 2012; Fransen
et al., 2012). Some crosstalk exists between these systems. For
instance, mitochondrial-produced ROS promote O•−2 generation
by NADPH oxidases, which may have important functions
during phagocytosis (Dikalov, 2011). It is currently unclear which
of the compartments above contributes the most to intracellular
ROS production, although mitochondria are often cited as the
main cellular ROS source (Brown and Borutaite, 2012).
The reactions involving ROS and their cellular targets lead
to the interconversion of various types of ROS (Figure 2).
For instance, mitochondrial- and cytoplasmic-produced O•−2
is dismutated to H2O2 by superoxide dismutases (SOD, EC
1.15.1.1). O•−2 is fairly unreactive to most electron-rich centers
due to its anionic charge, but it reacts with nitric oxide to
form peroxynitrite (Huie and Padmaja, 1993) and oxidizes iron-
sulfur clusters, thereby producing H2O2 and HO• (Rouault and
Klausner, 1996). These clusters are found inmultiple intracellular
compartments (Tong et al., 2000), and their oxidation by O•−2 (or
H2O2) leads to iron release and the inactivation of metabolically
important enzymes, such as those involved in amino acid
biosynthesis (Wallace et al., 2004) or carbohydrate metabolism
(Gardner et al., 1995). It is currently unclear whether most O•−2
is used toward nitric oxide metabolism, if it reacts with metal
clusters, or if it is dismutated to H2O2. Both dismutases and nitric
oxide react with O•−2 with near diffusion-limited rate constants (k
> 109 M−1 s−1, Bannister et al., 1973; Huie and Padmaja, 1993),
and O•−2 is very reactive with some iron-sulfur cluster-bearing
enzymes (k ≈ 106–107 M−1 s−1, Flint et al., 1993), but it is
unreactive with amino acid residues (Bielski and Shiue, 1979).
The fate of O•−2 depends on the local availability of the other
reactants or enzymes and likely varies between cells and under
different conditions, although it is generally assumed that most
O•−2 is dismutated to H2O2 (Forman et al., 2010).
In turn, H2O2 reacts slowly with most biological compounds,
such as free glutathione (k < 10 M−1 s−1, Winterbourn and
Metodiewa, 1999) and phosphatases (k ≈ 10–200 M−1 s−1,
LaButti et al., 2007;Marinho et al., 2014). However, it may display
extremely high reactivities with selected protein thiols due to
their neighboring chemical environment (k ≈ 105–108 M−1s−1,
Peskin et al., 2007; Trujillo et al., 2007; Manta et al., 2009). It
is decomposed into water and molecular oxygen as a result of
dismutation by catalases (EC 1.11.1.6), or it is reduced to water
by peroxidases and peroxiredoxins (EC 1.11.1.15). Often, several
of these mechanisms are present in the same cells. Protection
against H2O2 is accomplished through glutathione peroxidase,
catalase, and peroxiredoxin 2 in human erythrocytes (Johnson
et al., 2005; Low et al., 2007; Benfeitas et al., 2014). These defenses
are unlikely to be redundant in their functions: while catalase
is an efficient H2O2 scavenger, even under high oxidative loads,
peroxiredoxin 2 has limited reduction under such conditions
(Low et al., 2007), resulting in a lower contribution for H2O2
consumption. However, peroxiredoxin 2 and its coupled cycles
FIGURE 2 | Reactions involving ROS, antioxidant systems and energy metabolism. O•−2 and H2O2 are produced from oxygen through reactions that may oxidize
NADPH (dotted arrows, e.g., catalysis by NADPH oxidases). O•−2 is dismutated to H2O2 by SOD, and O
•−
2 and H2O2 may be converted to HO
• by Fenton reactions.
CAT, PRDX and GPX scavenge H2O2. The catalytic cycles of PRDX and TXN are represented, where SH and SS, respectively, indicate reduced and oxidized (disulfide)
thiols. Boxes and dashed arrows indicate the external processes with which the metabolites are associated. For example, XCT/CD44 mediates cysteine import, which
may then be incorporated into proteins, such as TXN and PRDX, or may be metabolized to yield GSH. Colors indicate proteins or processes from the same pathway.
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display desirable redox signaling properties (Benfeitas et al.,
2014), which are further discussed below.
O•−2 and H2O2 are also involved in the production of
HO• through iron-catalyzed Fenton reactions involving heme
peroxidases or iron/sulfur clusters (Fenton, 1894; Chen and
Schopfer, 1999; Koppenol, 2001). Iron accumulation and HO•
production have been extensively associated with carcinogenesis,
and iron chelators have been employed as therapeutic drugs
in cancer (reviewed by Torti and Torti, 2013; Bystrom and
Rivella, 2015). Due to its electrophilic nature, HO• preferably
oxidizes electron-rich sites, reacting with nucleic acids, lipids,
and proteins with diffusion-limited rate constants (Von Sonntag,
1987; Buxton et al., 1988; Stadtman and Levine, 2003; Sharma
and Rokita, 2013). This promotes DNA strand breaks, lipid
peroxidation and protein carbonylation, crosslinking, and
cleavage. The products of these reactions are toxic, and they often
promote radical propagation and damage to nearby molecules
through subsequent chain reactions. Importantly, due to HO•’s
very high and unselective reactions with biological compounds,
no cellular antioxidants can feasibly scavenge this oxidant before
it reacts with cellular contents. Instead, protection against the
toxic outcomes of HO• comes from preventing its formation
by shielding iron from ROS or by scavenging H2O2 and O
•−
2
before they yield HO•. The role of H2O2 in HO• formation and
consequential radical formation is also thought to be one of the
main reasons behind H2O2’s toxicity (Winterbourn, 1995).
As result of their different reactivities with biological
compounds, the above ROS present varying stabilities and
cellular roles. For instance, the fast and indiscriminate reactions
of HO• result in very small diffusion distances (≈80 Å, Roots
and Okada, 1975) that are approximately the size of a small
peptide. For this reason, HO• is likely to oxidize molecules
near its formation site (estimated half-life of 10−9 s, Pryor,
1986), and it is unfit to behave as a signaling molecule. O•−2
is also regarded as a poor signaling effector because it does
not permeate cell membranes and is quickly dismutated to
H2O2, or it reacts with iron/sulfur clusters and nitric oxide.
This results in low intracellular stability, hindering its diffusion
across large distances. Therefore, while O•−2 has some regulatory
properties, these properties are possibly due to its role in nitric
oxide and H2O2 metabolism (Brune, 2005; Thomas et al., 2006;
D’Autréaux and Toledano, 2007; Kaewpila et al., 2008; Labunskyy
and Gladyshev, 2013). In turn, H2O2 has emerged as the ROS
that displays the best signaling properties. Its high stability and
selective reactions with cellular compounds permit diffusion over
distances of several micrometers (Winterbourn, 2008) and enable
cell membrane crossing, which is also facilitated through specific
channels (Bienert et al., 2007). H2O2 reacts with cellular thiols,
including those contained in low molecular weight compounds,
such as glutathione, and protein thiols, such as peroxiredoxins
and thioredoxins (Box 1 and Figure 3). These reactions convert
an oxidizing equivalent into a redox signal, which may be
transduced from protein to protein via thiol disulfide exchange
or between glutathione and proteins, forming mixed disulfides.
Together with intracellular thiols, H2O2 regulates the redox state
and activity of several target proteins and has pivotal importance
in both physiological and pathological conditions (D’Autréaux
and Toledano, 2007). Due to this intricate association, any
discussion about the involvement of ROS in tumorigenesis
also needs to consider the role of thiols and other antioxidant
BOX 1 | Thiols as important redox signaling sensors and effectors.
Cysteine’s thiol side chains (R-SH) are often very reactive with H2O2. They undergo a series of reversible or irreversible redox transitions, which are represented
here through the catalytic cycles of a typical 2-Cys peroxiredoxin/thioredoxin (Figure 3). In this cycle, the reduced form is subsequently oxidized by H2O2 to sulfenic
(R-SOH) and sulfinic (R-SO2H) acids. The sulfinic form may be irreversibly oxidized to sulfonic (R-SO3H) forms in vitro, but it is currently unclear whether this process
occurs in vivo. Sulfinic acids may be reduced to sulfenic acids by specific proteins (e.g., sulfiredoxins, SRX) at the expense of ATP and the oxidation of TXN and
GSH (Chang et al., 2004). Sulfenic acids may also conjugate to form intra- or inter-molecular disulfide bonds (R-SS-R’). Disulfides are then reduced at the expense
of reducing equivalents, such as those found in NADPH (e.g., oxidized GSH or thioredoxin reduction by reductases), or by disulfide exchange with other proteins.
Therefore, cysteine oxidation by H2O2 may be transduced to partner proteins or small molecular weight compounds.
Due to their chemical and kinetic properties, the systems above have potentially different signaling properties. Although they exhibit slow reactivities with H2O2
when isolated (k ≈ 2.9 M−1 s−1 for free Cys, Winterbourn and Metodiewa, 1999), some cysteine thiols display extremely high reactivities (k ≈ 105–108 M−1 s−1
for peroxiredoxins, Trujillo et al., 2007; Manta et al., 2009). GSH is very abundant, but it is relatively unreactive with H2O2 per se, so the kinetics of glutathione
peroxidases should be considered when assessing glutathione’s intracellular role in H2O2 detoxification and signaling. These differences in reactivity also manifest
within the same pathway. Reduced and sulfenic forms quickly react with H2O2, unlike sulfinic and sulfonic acids, which are relatively unreactive with H2O2. The
process of thiol oxidation to disulfide exchange may transduce oxidative equivalents to target proteins, as observed in the proteins above (Jarvis et al., 2012;
Naticchia et al., 2013; Sobotta et al., 2015). For instance, thiol-disulfide exchange between peroxiredoxins and phosphatases/kinases is a mechanism for explaining
H2O2-induced signaling regulation despite the low reactivity of H2O2 with phosphatases/kinases (Ray et al., 2012; Marinho et al., 2014; Sobotta et al., 2015; Latimer
and Veal, 2016). Importantly, peroxiredoxin-mediated disulfide exchange controls the activity of several proteins involved in cancer (Park et al., 2007; Jarvis et al.,
2012; Sobotta et al., 2015), which reinforces the role of H2O2 and redox metabolism in this disease. Similar to disulfide exchange, the oxidation of glutathione may
lead to S-glutathionylation of proteins, which also regulates their activities (e.g., peroxiredoxin 2, Peskin et al., 2016). These and other properties possibly explain the
involvement of PRDXs and TXNs in redox signaling, and they point toward these proteins as good redox sensors and signaling transducers (Benfeitas et al., 2014;
Latimer and Veal, 2016; Netto and Antunes, 2016; Tomalin et al., 2016).
It should be noted that many of these redox systems depend on reducing equivalents to maintain their activity. Reducing equivalents are any molecules that act as
electron donors in reactions, typically in reference to NADH and NADPH. These species are used by several enzymes, such as reductases, which couple their oxidation
to the reduction of thioredoxin or glutathione. This provides another possible layer of selectivity in redox homeostasis: should NADPH utilization be prioritized toward
one system over another, the physiological role of the former would also be prioritized over the latter. Interestingly, the link between energy metabolism and redox
metabolism goes beyond NAD(P)H-enabling reductase activity. For instance, glyceraldehyde-3-phosphate dehydrogenase, an NADH-producing enzyme essential to
glycolysis, is inactivated by glutathionylation and H2O2-induced disulfide formation (Little and O’brien, 1969; Mohr et al., 1999). ROS and redox-coupled processes
thus not only consume reducing equivalents but also regulate energy metabolism.
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FIGURE 3 | Chemical cycle of PRDXs, TXNs, and GSH. The redox state of
PRDXs and TXN is indicated as follows: SH, reduced cysteine thiol; SOH,
sulfenic acid; SO2H, sulfinic acid; SS, disulfide. Orange dashed reactions
highlight disulfide exchange between peroxiredoxins and thioredoxins and
other proteins.
defenses. Although these systems have been widely studied in
cancer, the role of ROS, antioxidant defenses, and redox signaling
transducing partners in cancer is only now emerging beyond
antioxidant activities. Further ROS-centered studies aimed at
clarifying these properties and their involvement in cancer are
still required.
ROS AS ONCOGENIC DRIVERS AND
TARGETS OF THERAPEUTIC STRATEGIES
The role of ROS in cell physiology is highly dependent
on their levels. Under physiological levels, ROS regulate a
number of signaling processes by reacting with proteins, genes,
and transcription factors. ROS control adaptation to hypoxia,
regulation of differentiation, immunity, and longevity (Sena and
Chandel, 2012). However, the accumulation of ROS beyond
physiological levels promotes cell proliferation, angiogenesis,
and even apoptosis (D’Autréaux and Toledano, 2007; Cairns
et al., 2011; Figure 4), and ROS also control cell-cycle
progression (Menon and Goswami, 2007). Oncogene-induced
senescence promotes AMP-activated protein kinase activation,
mitochondrial dysfunction and ROS production, which trigger
senescence, thereby forming a positive feedback loop. Cancer
cells display high ROS production (Szatrowski and Nathan, 1991;
Ray et al., 2000), which is often also associated with antioxidant
imbalances (Skrzydlewska et al., 2005). This results in damage
to nuclear (Shibutani et al., 1991) and mitochondrial DNA
(Ishikawa et al., 2008;Weinberg et al., 2010).Mutations in nucleic
acids may be particularly toxic for the cell if they occur in tumor
suppressors or oncogenes. DNA mutations (Higinbotham et al.,
1992; Du et al., 1994), in turn, promote ROS generation, thereby
resulting in a vicious cycle of ROS production and mutagenesis
concomitant with high proliferation. Mitochondrial-generated
ROS are also essential for tumor aggressiveness and metastasis
(Ishikawa et al., 2008; Weinberg et al., 2010; Goh et al., 2011),
and increased cytoplasmic and mitochondrial ROS levels are
observed in metastatic nodules and circulating tumors when
compared to subcutaneous tumors (Piskounova et al., 2015).
FIGURE 4 | Targeting ROS homeostasis as a strategy for changing cell fate. In
proliferative conditions, such as cancer, targeting antioxidant systems could
move the redox state of the cell to either promote normal redox homeostasis
or apoptosis (strategies a and c, respectively). Unsuccessful tackling of
antioxidant metabolism results in the cells maintaining a proliferative state,
which potentially enhances malignancy. The three lines represent the high
heterogeneity between individuals, tissues, and cancer types.
ROS also stabilize the factors that drive tumor initiation and
progression (Gao et al., 2007), and promote protein oxidation
and the formation of toxic protein carbonyls (Stadtman and
Levine, 2003). Protein carbonylation is an irreversible process
present in cancer cells (Thanan et al., 2012). Carbonyls may
propagate to other proteins or lipids, which may result in
the formation of toxic byproducts through chain reactions.
ROS-induced lipid peroxidation products, such as 4-hydroxy-2-
nonenals, also have multiple physiological roles under low levels,
but they become toxic upon accumulation. These species also
accumulate in cancer cells (Skrzydlewska et al., 2005; Ayala et al.,
2014; Zhong and Yin, 2015).
Due to the toxic effects of ROS accumulation in cancer cells
and the fact that some ROS responses may be exclusive to
cancer cells but not to their healthy counterparts (Hileman et al.,
2004), antioxidants were envisioned as potentially important
drug targets in cancer treatment. Initial ROS-focused clinical
trials aimed to prevent ROS accumulation (Figure 4, strategy a).
In the Linxian study (Blot et al., 1993) stomach cancer patients
supplemented with selenium, vitamin E and β-carotene exhibited
lower mortality. However, antioxidant-supplemented diets often
failed to yield significant changes in cancer development, and
in some cases, these diets even promoted tumorigenesis and
metastasis (Omenn et al., 1996; Goodman et al., 2011; Klein
et al., 2011; Sayin et al., 2014). This is because cancer cells often
cope with increased ROS production by increasing the levels
of antioxidant defenses or reducing equivalents that maintain
their activity (Weinberg et al., 2010; DeNicola et al., 2011). This
effect is also observed in metastases, where metastatic melanoma
nodules are exposed to additional oxidative stress that is not
observed in established subcutaneous tumors, and the nodules
cope with this stress by promoting the expression of multiple
NADPH-producing pathways (Piskounova et al., 2015). High
antioxidant activities enable fast ROS-driven proliferation and
metastasization, but the increased oxidative stress is insufficient
to lead to apoptosis (Figure 4, strategy b). Higher antioxidant
expression is also associated with the radioresistance observed
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in certain cancer stem cell populations (Diehn et al., 2009).
In turn, recent antioxidant-targeted therapeutic strategies have
shifted their focus in the opposite direction, exploiting ROS
toxicity as a means leading to cancer cell apoptosis (Figure 4,
strategy c). These drugs often mimic ROS-generating enzymes
(e.g., NADPH oxidases and superoxide dismutases), inhibit
antioxidant enzymes (e.g., catalase), deplete thiol pools, such as
GSH, or shift redox buffer ratios (e.g., GSSG/2 GSH), thereby
promoting a more oxidizing intracellular state and cell apoptosis.
These strategies have been discussed in great detail in recent
reviews (Ushio-Fukai and Nakamura, 2008; Gupta et al., 2012;
Gorrini et al., 2013; Tong et al., 2015).
The targets of many of these drugs are not completely
understood, nor is it known whether the drugs are targeting
the best redox effectors. Are the targeted compounds selective
in treating cancer, but not healthy cells? Are they the best
target in that pathway? Which combined drug treatments could
improve treatment? These questions stem from an insufficient
understanding of redox metabolism in tumorigenesis, which is
greatly caused by the high variability in metabolic and redox
responses. For instance, different antioxidant defenses that target
the same ROS are up- and down-regulated in cancer cells
(Skrzydlewska et al., 2005), complicating the interpretation of
their role and that of their target ROS in cancer progression.
This high variability is even observed between individuals
with the same cancer type (Figure 5). Furthermore, genes
involved in the same processes are differentially expressed.
For instance, a high dispersion in gene expression levels is
observed within peroxiredoxins (PRDX1-6), thioredoxins (TXN
and TXN2), and thioredoxin reductases (TXNRD1-3), which are
highly conserved protein systems involved in H2O2 scavenging
and redox signaling transduction. As result of this variability,
redox-focused therapeutic strategies (Figure 4) must consider
patient-specific data to determine the best approach.
ROLE OF ANTIOXIDANT DEFENSES IN
CANCER
Imbalances in antioxidant defenses are one of the hallmarks of
cancer (Oberley and Oberley, 1997; Huang et al., 2000; Chung-
man Ho et al., 2001; Hu et al., 2005; Murawaki et al., 2008).
For instance, increased expression of SOD has been observed
in multiple cancers (Ray et al., 2000; Skrzydlewska et al., 2005;
Holley et al., 2012; Miar et al., 2015) and metastatic tissues
(Miar et al., 2015). Its overexpression promotes carcinogenesis
(Lu et al., 1997) and aggressiveness (Hempel et al., 2011). In
turn, SOD deficiency is associated with a higher cancer incidence
and DNA damage in mice (Van Remmen et al., 2003; Elchuri
et al., 2005), and it has also been observed in some cancers
(Oltra et al., 2001). SOD levels fluctuate throughout the cell
cycle and regulate growth factor cancer signaling (Nelson et al.,
2003; Juarez et al., 2008), cell cycle progression, and the energetic
changes of cells upon cancer transformation (Hempel et al.,
2011; Sarsour et al., 2014). Catalases, often regarded as the
main cellular defenses against H2O2 in human cells, may be
up- or down-regulated in cancer cells (Ray et al., 2000; Oltra
et al., 2001; Skrzydlewska et al., 2005; Glorieux et al., 2015).
Catalase treatment of highly metastatic cancer cell lines decreases
migration and invasion (Liu et al., 2012). Due to their antioxidant
FIGURE 5 | Antioxidant gene expression greatly varies between liver hepatocellular carcinoma in different subjects. The gene expression of 50 subjects was
downloaded from NCI’s Genomic Data Commons, and fragments per kilobase transcript per million (FPKM) were computed. FPKM-values lower than one were
considered to be non-expressed and were assigned a value of 0. The Log2(FPKM + 1) were then computed. Bars are colored according to processes of the same
pathway, as indicated on the left. Genes and respective proteins: CAT, catalase; GPX1-8, glutathione peroxidase; GSR, glutathione reductase; GCLM and GCLC,
glutamate-cysteine ligase modifier and catalytic subunits, respectively; GSS, glutathione synthetase; PRDX1-6, peroxiredoxin; TXN and TXN2, thioredoxin; TXNRD1-3,
thioredoxin reductase; SOD, superoxide dismutase; G6PD, glucose-6-phosphate dehydrogenase; TALDO1, transaldolase 1, TKT, transketolase, and PGD,
6-phosphogluconate dehydrogenase.
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activities and correlation with decreased aggressiveness in certain
tumors, catalases have been envisaged as potentially important
therapeutic agents (Glorieux et al., 2011; de Oliveira et al.,
2016). For instance, a recent study shows that catalase activity
correlates well with the ability of pancreatic cancers to resist
chemotherapeutic H2O2 treatment with ascorbate (Doskey et al.,
2016). In turn, altered levels of glutathione peroxidases are
amply reported in cancer (Lu et al., 1997; Skrzydlewska et al.,
2005), and the reduction potential of glutathione is associated
with the proliferative and apoptotic state of a cell (Buettner
et al., 2013). For instance, several glutathione peroxidases are
upregulated in hepatocellular cancer (Carlson et al., 2012), and
GPX4-deficient mice die shortly after birth (Carlson et al., 2016).
GPXs are responsible not only for reducing H2O2 but also for
reducing other ROS, such as lipid peroxides (Thomas et al., 1990;
Esworthy et al., 1993). Peroxiredoxins have also been associated
with tumorigenesis. PRDX1-4 and 6 display significantly altered
levels in some prostate cancers (Basu et al., 2011; Whitaker et al.,
2013). PRDXs may act as tumor suppressors (Egler et al., 2005),
and their increased gene expression is associated with metastasis
and aggressiveness (Park et al., 2006; Chang et al., 2007; Stresing
et al., 2012). For instance, PRDX2 is highly expressed in lung
metastases, and its knockdown decreases the formation of lung
metastasis (Stresing et al., 2012). PRDX2 is also highly expressed
in breast carcinoma, which correlates with the formation of
lung metastases. PRDXs are often upregulated in cancers, and
they contribute to cancer survival and resistance to oxidative
stress (Lu et al., 2014) and radiotherapy (Wang et al., 2005).
Interestingly, knockouts of the PRDX genes do not always result
in a favorable outcome. For instance, PRDX1 knockout mice
show premature death, increased DNA oxidation and increased
tumorigenesis and malignancy, and PRDX3 knockout results
in increased protein carbonylation in adipose tissues (see Cao
et al., 2009; Perkins et al., 2014 and references therein). These
observations show the crucial role of antioxidant enzymes in
cancerogenesis and survivability.
Alterations in antioxidant enzymes and ROS levels occur
throughout cancer progression. Overexpression ofmitochondrial
SOD2 acts as a tumor suppressor in skin and breast cancers
(Zhao et al., 2001; Robbins et al., 2012), suggesting that high
SOD activity promotes tumor initiation. However, SOD levels
also increase with tumor progression in these and other cancers
(Ray et al., 2000; Chung-man Ho et al., 2001; Dhar et al.,
2011; Miar et al., 2015), with similar changes occurring in other
antioxidants, such as cytoplasmic SOD1 and catalase (Miar et al.,
2015). Similarly, metastases show increased SOD2 protein levels
when compared with matched tissues, less metastatic cell lines,
or primary tumors (Liu et al., 2012; Miar et al., 2015). These
changes are often accompanied by directly proportional changes
in intracellular concentrations of H2O2, but they are not always
followed by changes in other antioxidants. Changes in ratios
of antioxidant proteins (e.g., SOD/catalase and SOD/GPX1)
translate into differential intracellular concentrations of H2O2,
and they vary with cancer stage and between metastatic and
primary tumor cells (Miar et al., 2015). These observations
show that while a comparison of the antioxidant expression
levels between cancer and matched tissues is informative, such
a comparison has to consider the developmental stage of the
cancer.
Importantly, these antioxidant defenses are not found in all
cell compartments, which should also differentially affect the
responses of cancer cells to therapeutic targeting. For instance,
mitochondria rely on superoxide dismutase 2, peroxiredoxin
3, thioredoxin 2, and thioredoxin reductase 2 for antioxidant
defense and signaling transduction, but they do not rely on
catalase (Rabilloud et al., 2001; Jones, 2006). Considering the
crucial role that mitochondrial-generated ROS have in cancer
initiation, progression, and apoptosis, the targeting of key
antioxidant and redox signaling transduction systems in this
compartment (e.g., PRDX3 Li and Yu, 2015) may have important
consequences for global cell metabolism. However, it should be
noted that targeting these antioxidants may lead to compensatory
responses by the other antioxidants. For instance, knockdown
of PRDX3 promotes the upregulation of other peroxiredoxins,
including those located in the cytoplasm (PRDX1-2 and PRDX6;
Li et al., 2008, 2013; Goncalves et al., 2012). This is particularly
important because these proteins may catalyze similar reactions
in H2O2 scavenging and disulfide exchange, albeit with different
mechanisms and specificities (Perkins et al., 2014).
In addition, cancer cells cope with increased intracellular
ROS by promoting the synthesis of compounds that enable their
activity (e.g., glutathione for GPXs, Buettner et al., 2013 and
TXNs for PRDXs, Arnér and Holmgren, 2006; Kaimul et al.,
2007). GSSG/GSH ratios are higher in many cancers (Oltra et al.,
2001; Skrzydlewska et al., 2005), in metastatic nodules and in
circulating tumor cells (Piskounova et al., 2015), and the enzymes
involved in GSH recycling or synthesis are often upregulated
(Carlson et al., 2012; Harris et al., 2015; Lien et al., 2016) as
response to oxidative stress. Mutations in PI(3)K/Akt, which are
common in some cancer types, such as breast cancer, stabilize
and activate NFE2L2, thereby promoting the upregulation of
enzymes involved in synthesizing or reducing GSH (glutathione
synthetase GSS, and glutathione reductase GSR; Lien et al.,
2016). Upregulation of GSS and GSR is also associated with
the increased resistance to oxidative stress observed in breast
cancer. The inhibition of GSH biosynthesis sensitizes cancer
cells to H2O2 and is potentiated by the utilization of other
antioxidant inhibitors (Lien et al., 2016). High intracellular
GSH concentrations also block drug-induced cytotoxicity in
myeloma cells (Starheim et al., 2016). Cumulative evidence
thus points toward GSH biosynthesis and homeostasis as a
therapeutic target. However, in some cancers, inhibition of
the GSH pathway alone does not prevent tumor progression.
In addition to GSS, GSH is also synthesized by glutamate-
cysteine ligase (GCL), an enzyme that consists of a heavy
catalytic (GCLC) subunit and a light regulatory (modifier,
GCLM) subunit. In mouse models of breast cancer, GCLM-
deficiency or GLCM inhibition by Buthionine-[S,R]-sulfoximine
(BSO) significantly prevented cancer initiation. However, this
effect occurs only before tumor onset, and BSO treatment after
onset does not alter tumor burden due to a compensatory
role of TXN (Harris et al., 2015). GSH and TXN both
serve as substrates for proteins with redox-important roles,
including glutathione peroxidases, peroxiredoxins, glutathione
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and thioredoxin reductases, glutaredoxins, and sulfiredoxins
(Björnstedt et al., 1994; Sun et al., 2001; Chang et al., 2004;
Johansson et al., 2004; Peskin et al., 2016). Several cancers
display increased expression of TXN and thioredoxin reductase
1 (TXNRD1) to compensate for GSH deficiency in GCLM−/−
cells (Mandal et al., 2010; Harris et al., 2015). The inverse is also
observed, where TXNRD1-deficiency promotes the expression of
GSR and GCLC, but not of PRDX1, CAT, or SOD1, in liver cancer
cells (Carlson et al., 2012). Given that GSH and thioredoxins
are relatively unreactive with ROS per se (Chae et al., 1994;
Winterbourn and Metodiewa, 1999), the promotion of GSH or
TXN biosynthesis is possibly promoting the peroxidase activities
of GPX and PRDX.
GLCM-deficient cells also present increased expression of the
cystine transporters and stabilizers XCT and CD44 (Lu et al.,
2015). This increased import is used toward promoting cysteine
biosynthesis, which, in turn, is used toward TXN biosynthesis.
Other observations show that chemotherapy treatment promotes
XCT and GCLM expression with a concomitant increase in
GSH biosynthesis in a HIF1-dependent mechanism related to
therapeutic resistance (Lu et al., 2015). Targeting XCT, GCLM,
and other pluripotency-involved transcription factors impaired
malignant transformation. It is currently unclear whether other
cysteine-based antioxidants, such as peroxiredoxins, also benefit
from increased cystine import. Importantly, it was also observed
that TXNs and thioredoxin reductases are upregulated and
co-localize in several cancers, particularly in more aggressive
cancers (Soini et al., 2001; Lincoln et al., 2003). These enzymes
are associated with tumor initiation (Shen et al., 2016), and
they correlated with worse prognosis (Cadenas et al., 2010).
TXNRD1 knockdown significantly slowed tumor progression
and metastasis in lung carcinomas (Yoo et al., 2006), but it
promoted cancer incidence in liver (Carlson et al., 2012).
Due to their chemical similarities and synergistic properties,
recent approaches have simultaneously targeted both TXN and
GSH metabolism, and they are significantly more effective
at reducing tumor volumes than when they are applied
individually (Harris et al., 2015). Multiple other studies have
shown this efficacy in combination with common cancer drugs
or radiotherapy for multiple cancers (e.g., Lu et al., 2007;
Sobhakumari et al., 2012; Rodman et al., 2016; Roh et al., 2016;
Tanaka et al., 2016). Together, the intracellular redox states
expressed in terms of reducing equivalents and thiol compounds
(Box 1) not only influence several signaling processes but also
control the reactivities of ROS and their redox partners by
regulating ROS homeostasis. It is currently unclear whether the
involvement of some of these antioxidant defenses in cancer is
related to their detoxification role, redox signaling properties
or both. For instance, PRDX2 has increased levels in some
cancer cells, which correlates with lower cytoplasmic H2O2
concentrations and cellular resistance to oxidative stress (Stresing
et al., 2012). PRDX2 displays peroxidase activity and is also
involved in redox signaling transduction (Neumann and Fang,
2007), such as the positive regulation of JNK-dependent DNA
repair (Lee et al., 2011). Since these H2O2-scavenging and
redox signaling properties stem from the kinetic properties of
PRDX2/TXN/TXNRD1, GPX1/GSH/GSR, and catalase systems
(Benfeitas et al., 2014; Tomalin et al., 2016), further studies
are required to understand whether the culprit of PRDX2’s
tumorigenic association is its role as a peroxidase, chaperone, or
redox signaling transducer. It is unclear whether the alterations
in GSH/TXN biosynthesis and PRDX/GPX levels are more
important toward controlling redox signaling, detoxification, or
both. For instance, some observations indicate that sulfiredoxins
and peroxiredoxins promote tumor growth and metastasis
by modulating phosphokinase signaling cascades (Wei et al.,
2011). Do these proteins directly interact with their targets?
PTEN binds to PRDX1, but not to PRDX2, and this promotes
Akt-mediated proliferation (Cao et al., 2009). The PRDX1-
PTEN complex dissociates upon H2O2-mediated oxidation. A
localized accumulation of H2O2, such as that occurring near
cell membranes or near ROS sources, would thereby alter
PTEN-mediated signaling transduction and proliferation by
direct PRDX1 oxidation (Woo et al., 2010) or by relaying
a redox signal from another more abundant, H2O2-reactive
PRDX. PRDX2 is a good candidate as a H2O2 sensor due to
its high reactivity with H2O2 (k ≈ 107–108 M−1 s−1), and
it was recently observed to transmit oxidative equivalents to
the transcription factor STAT3 (Sobotta et al., 2015), thereby
controlling tumor proliferation and survival (Yu et al., 2014).
While disulfide exchange between PRDX1 and 2 remains to be
shown, the above observations indicate that the direct reactions
of peroxiredoxins with transcription factors are important
proliferative processes controlled by H2O2. It also remains to
be seen whether the promotion of TXN biosynthesis (Harris
et al., 2015), which is often linked to added ROS protection,
is instead enabling secondary signaling transduction reactions,
and whether multiple PRDX isoforms act synergistically in
this process. Studying cancer ROS metabolism should therefore
consider the toxicity of these oxidants and signaling disruption.
Overall, the observations above highlight important features
that should be considered in cancer studies. First, targeting
one antioxidant defense may elicit compensatory behaviors
by other antioxidant defenses. Second, the close relationship
between antioxidant proteins (e.g., GPX and PRDX) and their
redox partners (e.g., GSH and TXN) requires that the choice
of suitable therapeutic targets considers possible synergisms
between them. Third, the high variability in responses, even
for the same tumor, requires that cancer treatment is designed
in a case- and stage-specific manner, rather than a cancer-
type approach. Finally, all of these considerations need to be
considered to identify antioxidant pathways that are differentially
regulated by cancer, but not by normal cells. The targeting
of antioxidant defenses as an approach for cancer treatment
should therefore require tissue- and subject-specific phenotypic
characterization.
ENERGETIC CHANGES ARE COUPLED
WITH MAINTENANCE OF THE
ANTIOXIDANT ACTIVITY IN CANCER
Cancer cells display increased glycolytic activity and lower
mitochondrial oxidative phosphorylation. Glucose uptake by
breast, liver, colorectal, lung, and pancreatic cancers may
reach 8–15 times the fluxes observed by surrounding normal
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tissues (see Boros et al., 1998 and references therein). This
metabolic shift, characterized by increased ATP production
from glycolytic pathways rather than respiratory pathways, even
under aerobiosis, is one of the most well-known metabolic
hallmarks of cancer cells, and it is generally referred to as
the Warburg effect (Warburg, 1956). This process is crucial to
maintaining the high energetic demand of fast proliferative cells.
However, the energetic changes extend beyond the Warburg
effect and are intimately related to the redox responses of
cancer cells. This is the case of the metabolic changes that
alter NADPH production. For instance, the MYC-controlled
expression of pyruvate kinase type M2 (PKM2) is higher
in cancer cells and promotes the diversion of carbohydrate
metabolism from glycolytic pathways to other pathways (Vander
Heiden et al., 2009), including the pentose phosphate pathway
(PPP). Carbohydrates are thus diverted from ATP production
to generate reducing equivalents and building blocks, such
as phosphopentoses and ribonucleotides, supporting the fast
proliferation of cancer cells (Boros et al., 1997; Raïs et al., 1999).
Because ROS also regulate carbohydrate metabolism (Robbins
et al., 2012; Hart et al., 2015; Miar et al., 2015) and some enzymes
couple redoxmetabolism andATP phosphorylation (Chang et al.,
2004), the crosstalk between energetic and redox metabolism
extends beyond enabling NADPH-driven peroxidase antioxidant
activities.
Many of the glycolytic and PPP enzymes that are involved
in NADPH production are elevated in cancer cells. Glucose-
6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate
dehydrogenase (6PGD), which are both enzymes of the oxidative
branch of PPP, catalyze the production of NADPH from hexoses
entering the PPP from either glycolysis or the non-oxidative PPP.
G6PD’s activity is promoted by multiple oncogenic pathways
upregulated in cancer (Stanton et al., 1991; Tian et al., 1994; Au
et al., 2000; Wang et al., 2012; Zhang et al., 2014), and multiple
studies have proposed that G6PD has pro-oncogenic activities
(Wang et al., 2012; Patra andHay, 2014; Zhang et al., 2014).G6PD
overexpression leads to higher levels of intracellular NADPH,
GSH, and nucleotide precursors, increased health span, and
lower nucleotide oxidation (Nóbrega-pereira et al., 2016). These
observations provide a clear link between PPP-mediated NADPH
production and oxidative stress. In turn, G6PD deficiency
severely limits cell resistance to oxidative stress (Pandolfi et al.,
1995) and promotes oxidative damage to DNA (Jeng et al.,
2013). These observations raise the hypothesis that a targeted
inhibition of G6PD may be conducive to oxidative imbalance
and ROS-mediated cell death. Considering that G6PD catalyzes
the first and rate-limiting step of PPP and that it has a role
in controlling the intracellular redox environment, this enzyme
has been envisaged as one of the potentially most important
therapeutic cancer redox targets (Wang et al., 2012; Patra and
Hay, 2014; Zhang et al., 2014; Nóbrega-pereira et al., 2016), and
it has been included in pre-clinical trials (Budihardjo et al., 1998;
De Preter et al., 2015). 6PGD is also upregulated in many cancers,
including thyroid (Giusti et al., 2008), lung (Sukhatme and Chan,
2012), and cervical (Jonas et al., 1992) tumors. This enzyme is
important for proliferation and tumor growth (Sukhatme and
Chan, 2012; Shan et al., 2014), and its inhibition promotes
senescence in lung cancer (Sukhatme and Chan, 2012). This
phenotype results from altered glucose levels, but not altered
NADPH levels (Sukhatme and Chan, 2012; Lin et al., 2015),
suggesting that NADPH metabolism, and ultimately glucose
metabolism, may adapt in such a way that compensates for the
selective targeting of the PPP’s enzymes. Interestingly, 6PGD
suppression limits lipid biosynthesis and elevates intracellular
ROS levels, and this effect translates into decreased tumor growth
(Lin et al., 2015). However, conflicting observations regarding its
importance in cancerogenesis (Sukhatme and Chan, 2012; Lin
et al., 2015) also suggest that its role may vary depending on tissue
and oncogenic background (Lin et al., 2015).
Other enzymes also promote downstream NADPH
production. For instance, transketolase (TKT) and transaldolase
(TALDO) are both enzymes of the non-oxidative PPP. While
neither of them catalyze NADPH production, they are both
important in directing the phosphorylated pentoses generated
in the PPP back to glycolysis. Both enzymes are upregulated in
cancer (Heinrich et al., 1976; Liu et al., 2010). TKT is required
for cancer growth and controls resistance to oxidative stress
by modulating NADPH levels. Its inhibition leads to higher
intracellular ROS and decreased NADPH/NADP+ ratios (Xu
et al., 2016), and it sensitizes cells to drug treatment. Importantly,
TKT knockdown increases oxidative PPP fluxes, but it also leads
to lower NADPH levels, which is a striking observation
considering that NADPH is produced through the oxidative
PPP; this point remains to be clarified. TALDO’s expression is
linked to metastasis in hepatocellular carcinoma (Wang et al.,
2011). TALDO deficiency also elicits hepatocellular carcinoma
and promotes the formation of malignant tumors (Hanczko et al.,
2009). These outcomes are associated with redox imbalances
(lower NADPH and GSH levels) due to the insufficient recycling
of PPP metabolites to support NADPH production, and they
are reverted with dietary supplementation of antioxidants. This
insufficient recycling exposes the liver to added oxidative stress
and decreases lifespan. Other NADPH-producing enzymes are
also upregulated in cancer cells, and some of the isoforms are
exclusive to proliferating cells (Mazurek et al., 2005), suggesting
that these enzymes may be selective therapeutic targets. Altered
glycolytic and PPP metabolism has been proposed for potential
therapeutic targeting in cancer (Wang et al., 2012; Patra and
Hay, 2014; Zhang et al., 2014; Wen et al., 2015; Hay, 2016).
Importantly, the crucial role of the PPP in cancer development
seems to be associated with its redox homeostasis properties
rather than its production of ribonucleotide precursors, as
observed in hepatocellular carcinoma (Xu et al., 2016). Further
studies are required to understand whether similar observations
are present in other cancers.
While the oxidative PPP represents the main source of
cytoplasmic NADPH in proliferating cells (Fan et al., 2014), other
sources contribute significantly. Serine (Mehrmohamadi et al.,
2014), folate (Tedeschi et al., 2013; Fan et al., 2014; Piskounova
et al., 2015), and malate (Jiang et al., 2013) pathways also produce
and regenerate NADPH and have crucial roles in maintaining
the redox status and buffering oxidative stress in cancer cells. A
system-wide comparison the contributions of these pathways to
NADPH production and ROS metabolism in cancer is beginning
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to emerge (e.g., Tedeschi et al., 2013; Mehrmohamadi et al.,
2014). In the context of antioxidant defense, most of these studies
have focused on GSH-mediated ROS protection due to the close
relationship between the PPP, serine/glycine metabolism, and
de novo GSH biosynthesis. However, an analysis addressing the
role of these pathways in supporting the activities of other
important antioxidant defenses and redox signaling processes
is currently missing. This becomes an important issue because
defenses have different reducing equivalent requirements for
activity, which also reflect their different antioxidant capacities
and redox signaling roles. For instance, while antioxidant systems
like PRDX/TXN/TXNRD and GPX/GSH/GSR stoichiometrically
couple ROS detoxification to NADPH consumption, others, such
as catalase, scavenge ROS while oxidizing virtually no NADPH.
In normal cells, where energetic metabolism is limited, NADPH
must be utilized toward lipid and cholesterol biosynthesis,
and ROS decomposition by NADPH-consuming systems is
thus an energetically expensive process. In cancer cells, where
NADPH-producing fluxes are promoted, NADPH may be
sufficiently abundant for cells to afford utilizing PRDX- or
GPX-mediated detoxification. Importantly, the differences in the
energetic requirements and kinetics of the PRDX/TXN/TXNRD,
GPX/GSH/GSR, and catalase systems become particularly
important if cancer treatments are targeting ROS metabolism
by inhibiting NADPH production. ROS defenses may then
be maintained by catalase or other energetically inexpensive
processes, which is similar to what is observed in non-cancerous
cells (Johnson et al., 2005; Benfeitas et al., 2014). Nevertheless,
the lower cancer progression and increased ROS levels induced
by the inhibition of NADPH-producing pathways indicate that
this is a viable cancer therapy. A further understanding of the
energetic requirements of antioxidant defense (e.g., PRDX/TXN
vs. GSH/GPX pathways) may permit an efficient combination
of anti-oxidant- and energetic-focused drug utilization for
effective cancer treatment. Importantly, the heterogeneous
gene expression and synergistic responses that may occur
between alternative metabolic pathways at different cancer stages
require an assessment of possible targets that considers specific
oncogenic backgrounds.
SYSTEMS BIOLOGY AND PERSONALIZED
MEDICINE APPROACHES ARE
FUNDAMENTAL TO REVEALING REDOX
RESPONSE IN CANCER
The observations above highlight the extensive crosstalk within
and between ROS detoxification, redox signaling transduction,
energy metabolism, and central metabolism. As such, the
therapeutic targeting of cancer is more effectively strategized by
addressing multi-pathway dysregulation (Pawson and Linding,
2008). Thus, while targeting the activity of specific enzymes
may yield promising results in vitro and to a certain extent, in
vivo, methods that encompass global metabolism are required
to devise viable, cancer-specific treatment targets. Furthermore,
these redox responses are highly heterogeneous, as has been
observed by the different redox responses displayed by different
cancer types, between individuals with the same cancer type,
and between different cancer stages. Finding the best targets
(Figure 4) and elucidating the mechanisms behind cancer
phenotypes hence requires integrative analysis of a large number
of biological networks, together with tissue- and patient-tailored
data.
Systems biology aims at analyzing assorted biological data
(e.g., genomics, proteomics, metabolomics, fluxomics), and
it has consistently assisted in understanding the complex
underlying mechanisms in health and disease (Mardinoglu
and Nielsen, 2012; Agren et al., 2014; Benfeitas et al., 2014;
Ghaffari et al., 2015b; Mardinoglu et al., 2017). Using systems
biology approaches, others successfully clarified the role of small
molecular decision circuits (e.g., Faratian et al., 2009; Gaglio
et al., 2011; Tyson et al., 2011) and found commonalities across
different cancers through pan-cancer analyses (e.g., Weinstein
et al., 2013; Zack et al., 2013; Leiserson et al., 2014; Aran
et al., 2015; Peng et al., 2015). However, few studies have
addressed ROS metabolism using systems approaches (Zhang
et al., 2010; Zhou et al., 2011; Zhan et al., 2012). For instance,
modeling of the NFE2L2 pathway suggests that the high
NFE2L2 expression that typically occurs in cancer cells promotes
chemoresistance (Zhan et al., 2012) and suggests apparently
opposite roles in antioxidant and ROS-mediated cancer signaling
(Zhang et al., 2010). However, certain antioxidants, such as
peroxiredoxins, display both scavenging and redox sensor and
signaling transducer properties (Box 1). Mathematical modeling
of H2O2 metabolism indicates that cancer-related transcription
factors are unlikely to be activated by direct reaction with H2O2,
and it points toward protein thiols as the likely signaling sensors
and transducers. Others have observed that the glutathione
and NADPH synthesis pathways are simultaneously up- or
down-regulated in breast, ovary, colon and lung cancers,
establishing important interactions with de novo nucleotide
synthesis (Mehrmohamadi et al., 2014), which suggests that
cancers utilize redox homeostasis and biosynthesis pathways in
parallel. ROS and redox responses of cancer cells have yet to be
more extensively examined.
With the advent of big data, recent approaches aimed
at understanding cell metabolism now incorporate large
reaction networks derived from omics technologies (genomics,
transcriptomics, proteomics, and others). By encompassing
whole-cell reaction networks, GEMs have helped identify
important redox alterations in metabolic diseases and
physiological processes. For instance, disturbed H2O2
metabolism is observed (Mardinoglu et al., 2017) in non-
alcoholic fatty liver disease, specifically due to deficient GSH
biosynthesis (by GCLC/GCLM, GSR) and NADPH production
(NNT). A lower abundance of plasma glycine, a substrate for
de novo GSH biosynthesis, is also found in subjects with high
hepatic steatosis. Observations in mice (Mardinoglu et al.,
2015b) indicate that commensal gut microbes decrease glycine
availability in the gastro-intestinal tract of the host, which results
in decreased de novoGSH synthesis and promotesNNT and GSR
expression, possibly to compensate for the decreased GSH pool.
In the context of cancer, publicly deposited genomic data permit
the stratification of cancer patients based on network-specific
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mutations (Hofree et al., 2013), and these data have been used to
find biomarkers and potential cancer therapeutic targets (Jerby
and Ruppin, 2012; Agren et al., 2014). Others have combined
experimental and interactome data with stochastic modeling to
find that ROS and DNA damage are necessary and sufficient for
senescent growth arrest (Passos et al., 2010). Chronic, non-toxic
ROS supplementation reverses drug resistance in carcinoma cells
(Maiti, 2010), which, through pathway analysis, identified several
genes (e.g., TP53, Rac/Cdc42 guanine nucleotide exchange factor
6 ARHGEF6, and a DNA-activated protein kinase PRKDC) that
mediate ROS-related apoptosis. Reconstruction of a generic
human whole-cell GEMs encompassing >9,000 reactions
and >3,000 metabolites and genes (Mardinoglu et al., 2014a)
enabled context-specific integration and interpretation of cancer
omics data. Comparisons between hepatocellular carcinoma
and healthy liver samples using these models indicate that
tumors display an increased abundance of NADPH-producing
enzymes (e.g., ME1, G6PD, TALDO1, and TKT) and that H2O2
may be used as reporter metabolite in some of the patients
(Bjornson et al., 2015). Personalized medicine approaches
would greatly benefit from clarifying redox cancer responses.
GEMs were previously used to identify novel anticancer drugs
by reconstructing patient- and tissue-specific GEMs (Agren
et al., 2014) and to identify anti-growth factors in human
cancer cell lines (Ghaffari et al., 2015a). Cell-specific GEMs
have also been used to identify malonyl-CoA decarboxylase,
an important enzyme in fatty acid metabolism, as a selective
and effective cancer therapeutic target (Yizhak et al., 2014a). Its
inhibition drains reducing equivalents, decreases GSH/GSSG
ratios, and promotes oxidative stress, which may help in
chemotherapeutic approaches. Patient-specific breast and lung
cancer GEMs were also able to predict patient survivability, and
they predicted that knockout of GSR significantly affects cancer
growth.
FIGURE 6 | Personalized systems medicine approaches are emerging as useful tools in devising patient-specific, rather than population-based, therapeutic targets in
cancer. Tumor profiling of patients may help in identifying up- and down-regulated pathways (continuous and dashed arrows, respectively) that are suitable for
therapeutic targeting. Drug targeting of specific processes (red arrows), either to promote or inhibit the processes, will permit alterations in the consequences of redox
processes in cancer and other diseases.
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Interestingly, despite an enzyme- or process-specific focus in
redox cancer metabolism in recent years, system-wide studies
of ROS and redox metabolism and their interactions with
central metabolism in multiple cancers are lacking. Antioxidant
profiling of tumor cells and their surrounding cells may be
used in conjunction with patient-specific GEMs to identify
the best therapeutic targets in this disease (Figure 6). Studies
using reaction network information with tissue- and patient-
specific models will be useful in (1) Redox profiling of patient-
specific cancer tissues; (2) Understanding mechanistic properties
of redox responses; (3) Devising effective, selective and patient-
specific therapeutic strategies to regulate redox responses; (4)
Establishing redox-based therapies to synergize with existent
drugs (Kasiappan and Safe, 2016) and identifying and averting
drug-resistance mechanisms; and (5) Shortening the gap between
pre-clinical and clinical trials, potentially overcoming issues faced
by previous trials, such as those that assessed the impact of
dietary antioxidants on cancerogenesis (Omenn et al., 1996;
Goodman et al., 2011; Klein et al., 2011; Sayin et al., 2014).
The adopted strategies (Figure 6) will benefit from patient-
specific tumor profiling to identify single or multiple targetable
processes within the same pathway or to identify processes
that serve as metabolic central hubs. The combination of these
approaches with drugs that target other metabolic processes
may promote desirable synergisms. Redox systems medicine is
thus an interesting emerging field with potentially important
implications for disease treatment.
CONCLUSION
Redox, energetic and central metabolism are closely intertwined,
and the view that ROS are simple secondary products of
cell metabolism is long gone. Together with their redox
partners, ROS and antioxidant defenses are now regarded as
crucial processes in tumorigenic initiation, progression and
aggressiveness. However, the redox cancer responses are highly
heterogeneous, manifesting not only between different cancer
types but also between patients who suffer from the same
cancer, and they are altered throughout cancer progression.
The influence of ROS on different biochemical levels makes it
necessary to seek an integrative analysis of these systems at the
genomic, proteomic, and metabolomic levels. Approaches that
are able to encompass these levels and integrate the crosstalk
between antioxidant, redox, energetic, and central metabolism
are able to capture and understand these complex responses.
Systems biology approaches may be used to analyze omics data
and understand the roles of each redox system in cancer. These
approaches may be tissue- and patient-tailored, which enables
the identification of the best therapeutic targets, while taking
in account patient-specific oncogenic backgrounds. This is the
aim of personalized systems medicine (Mardinoglu and Nielsen,
2015; Schork, 2015), an emerging field that presents a high
potential to overcome some of the problems in therapeutic
treatments, including the low (<25%) drug efficacies caused
by population—rather than patient-wise data (Schork, 2015).
Together with existing drugs, novel or existing redox-targeting
drugs may be identified to produce synergistic responses for the
treatment or prevention of cancer. Personalized medicine may
thus enable an understanding of the role of redox systems in
cancer and other diseases and may assist in drug discovery.
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